Compare SLDPW & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDPW | CRL |
|---|---|---|
| Founded | 2011 | 1947 |
| Country | United States | United States |
| Employees | 230 | N/A |
| Industry | Electrical Products | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 9.0B |
| IPO Year | N/A | 1999 |
| Metric | SLDPW | CRL |
|---|---|---|
| Price | $0.32 | $178.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $198.27 |
| AVG Volume (30 Days) | 35.4K | ★ 656.5K |
| Earning Date | 02-27-2025 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $18,026,000.00 | ★ $1,857,601,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $0.08 | $132.58 |
| 52 Week High | $2.33 | $228.88 |
| Indicator | SLDPW | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 54.33 | 56.21 |
| Support Level | $0.29 | $147.06 |
| Resistance Level | $0.40 | $182.76 |
| Average True Range (ATR) | 0.04 | 6.78 |
| MACD | 0.01 | -0.44 |
| Stochastic Oscillator | 43.38 | 59.88 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.